Differential cell counters
This article was originally published in The Gray Sheet
Executive Summary
Automated systems will be reclassified from Class III to Class II with special controls based on information submitted in a reclassification petition by the International Society for Laboratory Hematology, FDA proposes in a May 9 Federal Register notice. FDA had previously rejected a downclassification submission filed by Abbott (1"The Gray Sheet" Jan. 25, 1999, p. 8). The guidance "Automated Differential Cell Counters for Immature or Abnormal Blood Cells" will serve as a special control. Comments are due by Aug. 7
You may also be interested in...
Sysmex Sees ADCC Downclassification As Smoothing Path To HPC Indication
Sysmex Corporation expects the new Class II designation for automated differential cell counters (ADCCs) used to count and classify abnormal cells in the blood will facilitate the firm's quest to expand labeling for its SE series automated hematology analyzer.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.